Therapeutic Monoclonal Antibodies Market – Is Biologics the Answer to Rising Disease Incidence?
Frost & Sullivan Looks at the Future of Disease Therapeutics
Existing adoption rates and commercial success of launched monoclonal antibodies (mAbs) for therapeutics have established a strong platform for these products. Broadening the horizontal indications for existing mAbs, expanding the applications of mAbs in new therapeutic areas and developing innovative and faster drug delivery mechanism are the current trends in the mAbs market.
Monoclonal Antibodies (mAbs) are mono-specific high molecular weight complex proteins which are capable of post translational modifications like glycosylation.
They are predominantly used in the treatment of cancer and autoimmune and inflammatory disorders. Other areas include cardiovascular and infectious diseases and organ transplants. Over 45 mAbs are currently used. Drugs developed for cancer and Rheumatoid Arthritis (RA) account for 75 % of the total market.
The European therapeutic monoclonal antibodies market, accounting for approximately 33.1 % of the global market, is estimated at $19.01 billion in 2011 and is expected to reach $42.37 billion in 2018 with a CAGR of 12.1 %.
“Robust activities and strong product potential across both existing and pipeline products drive M&A activities across the monoclonal antibodies market,” explains Deepika Pramod Chopda, Research Associate at Frost & Sullivan. “The alliances commonly observed include that of Big Pharma acquiring small biotech companies helping growth and development across the biologics industry.”
While a strong product pipeline, premium pricing trends and growing market opportunities and success from existing product line-up drive the mAbs market, high developmental costs, the financing of mAbs therapeutics in public healthcare , alternative treatment options within biologics and competition from biosimilars are all factors impeding the market growth.
Therapeutic Monoclonal Antibibodies market for their innovative and lucrative offerings into the biopharmaceuticals market resulted in a positive revenue growth rate through the economic recession. “Growing demand for improvised therapy allure mAbs against conventional chemical drugs for therapeutics,” concludes Ms Chopda. “Strong pipeline and broadening product segments to ophthalmology, respiratory infections will promote their development.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
